Evolving Our Partnership: The CSER2 Centralized Support Coordinating Center

发展我们的合作伙伴关系：CSER2 集中支持协调中心

• 批准号: 9907352
• 负责人: Stephanie Malia Fullerton
• 金额: $ 44.59万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-04-01 至 2021-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9907352
• 关键词: Abbreviations; Address; Area; Caring; Clinical; Clinical effectiveness; Communities; Computerized Medical Record; Consensus; Data; Development; Discipline; Economics; Effectiveness; Electronic Health Record; Family member; Generations; Genetic Medicine; Genomic medicine; Genomics; Goals; Individual; Informatics; Institutes; Investigation; Investments; Knowledge; Lead; Leadership; Letters; Logistics; Medical Genetics; Medicine; National Heart, Lung, and Blood Institute; National Human Genome Research Institute; Outcome; Patient-Focused Outcomes; Patients; Pharmacogenomics; Phase; Physicians; Population; Publications; Reader; Recommendation; Research; Research Activity; Research Personnel; S Phase; Science; Sequence Analysis; Site; Technology; Text; Time; Translating; United States National Institutes of Health; Universities; Washington; Work; base; clinical care; clinical heterogeneity; clinical sequencing; economic outcome; ethical legal social implication; evidence base; exome sequencing; experience; genome sequencing; health economics; improved; meetings; novel; patient oriented; patient population; programs; success; synergism; working group

Abstract The overall goal in this competitive renewal proposal for the Clinical Sequencing Exploratory Research (CSER) Consortium coordinating center (CC) is to enhance the effectiveness of the next CSER phase (CSER2) by assuring the effective coordination and logistic support needed to propel cross-consortium efforts and to identify new synergies that increase the scientific value of the individual projects. CSER2 will continue to generate the evidence base required for clinical genomic medicine, expanding its reach into non-academic centers and enhancing the diversity of the patient groups. It will provide timely, pragmatic information about best practices for genomic medicine that permit optimal provide useful and accessible recommendations for physicians, patients, family members, and policymakers. In approaching this task, we will leverage our considerable experience as the existing CSER CC and as partners in many other genomics consortia, including expertise in diverse and non-academic populations to facilitate the work of CSER2. In the current cycle of CSER (CSER1) the UW CC has made numerous significant contributions to the important work of CSER, as outlined in the progress section. Our success is underscored by the fact that the PIs at every CSER1 UO1 site support UW continuing as the CSER2 CC. Specific Aims Aim1: Provide the leadership, organizational, and logistical support to facilitate and integrate the activities required for the success of the CSER2 consortium, its subcommittees, and work groups. Aim 2: Provide unique expertise to facilitate excellence and consortium-wide products in the key program areas: ELSI (ethical, legal, and social implications), medical genetics and care integration, sequencing technology and sequence analyses, informatics and electronic medical record integration, health economics, and patient-centered outcomes. Aim 3: Optimize development and distribution of CSER2 data and products and facilitate interactions with other relevant NIH programs and with the larger community of stakeholders.

摘要 临床测序探索性研究的竞争性更新提案的总体目标 （CSER）联合体协调中心（CC）是为了提高CSER下一阶段的有效性 （CSER2）通过确保推动跨联盟所需的有效协调和后勤支持， 这将有助于加强这些努力，并确定能提高各个项目科学价值的新的协同作用。CSER 2 将继续为临床基因组医学提供所需的证据基础，扩大其覆盖范围 进入非学术中心，提高患者群体的多样性。它将提供及时， 实用信息的最佳做法，为基因组医学，允许最佳提供有用的， 为医生、患者、家庭成员和决策者提供可访问的建议。在接近 在这项任务中，我们将利用我们作为现有CSER CC和合作伙伴的丰富经验， 许多其他基因组学财团，包括在不同的和非学术人口的专业知识，以促进 CSER 2的工作。在当前的CSER周期（CSER1）中，UW CC做出了许多重要的决定， 对CSER重要工作的贡献，如进度部分所述。我们的成功是 每个CSER 1 UO 1研究中心的PI支持UW继续作为CSER 2 CC。 具体目标 目标1：提供领导、组织和后勤支持，促进和整合 CSER2联合体及其小组委员会取得成功所需的活动， 组 目标2：提供独特的专业知识，以促进卓越和联盟范围内的产品， 计划领域：ELSI（伦理，法律的和社会影响），医学遗传学和护理 整合，测序技术和序列分析，信息学和电子 医疗记录整合，卫生经济学和以患者为中心的结果。 目标3：优化CSER2数据和产品的开发和分发， 与其他相关的NIH计划和更大的利益相关者社区的互动。